Article Text
Editorial
Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?
Statistics from Altmetric.com
Footnotes
Competing interests JPP receives research funding from ARCA biopharma, Boston Scientific, Gilead, Janssen Pharmaceuticals, ResMed and St Jude Medical and provides consulting to Amgen, Johnson & Johnson, Medtronic and Spectranetics.
Provenance and peer review Commissioned; internally peer reviewed.